- Home
- CLDI vs ACXP Comparison
CLDI vs ACXP Comparison
Compare CLDI & ACXP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CLDI
- ACXP
- Stock Information
- Founded
- CLDI 2014
- ACXP 2017
- Country
- CLDI United States
- ACXP United States
- Employees
- CLDI N/A
- ACXP N/A
- Industry
- CLDI Biotechnology: Biological Products (No Diagnostic Substances)
- ACXP Biotechnology: Pharmaceutical Preparations
- Sector
- CLDI Health Care
- ACXP Health Care
- Exchange
- CLDI Nasdaq
- ACXP Nasdaq
- Market Cap
- CLDI 10.2M
- ACXP 8.4M
- IPO Year
- CLDI N/A
- ACXP 2021
- Fundamental
- Price
- CLDI $0.23
- ACXP $0.43
- Analyst Decision
- CLDI Strong Buy
- ACXP Strong Buy
- Analyst Count
- CLDI 1
- ACXP 2
- Target Price
- CLDI $10.00
- ACXP $10.00
- AVG Volume (30 Days)
- CLDI 1.8M
- ACXP 18.4M
- Earning Date
- CLDI 08-12-2025
- ACXP 08-08-2025
- Dividend Yield
- CLDI N/A
- ACXP N/A
- EPS Growth
- CLDI N/A
- ACXP N/A
- EPS
- CLDI N/A
- ACXP N/A
- Revenue
- CLDI N/A
- ACXP N/A
- Revenue This Year
- CLDI N/A
- ACXP N/A
- Revenue Next Year
- CLDI N/A
- ACXP N/A
- P/E Ratio
- CLDI N/A
- ACXP N/A
- Revenue Growth
- CLDI N/A
- ACXP N/A
- 52 Week Low
- CLDI $0.20
- ACXP $0.30
- 52 Week High
- CLDI $3.89
- ACXP $3.33
- Technical
- Relative Strength Index (RSI)
- CLDI 21.13
- ACXP 47.99
- Support Level
- CLDI $0.31
- ACXP $0.52
- Resistance Level
- CLDI $0.33
- ACXP $0.63
- Average True Range (ATR)
- CLDI 0.04
- ACXP 0.09
- MACD
- CLDI -0.01
- ACXP 0.00
- Stochastic Oscillator
- CLDI 14.83
- ACXP 17.33
About CLDI Calidi Biotherapeutics Inc.
Calidi Biotherapeutics Inc is a clinical-stage immuno-oncology company with technology designed to arm the immune system to fight cancer. The Company's stem cell-based platforms utilize potent allogeneic stem cells capable of carrying payloads of oncolytic viruses for use in a many oncology indications, including high-grade gliomas and solid tumors. Its products include CLD-101 for Recurrent HGG; CLD-201 for Solid Tumors, and CLD-400 for certain lung cancer and Metastatic Solid Tumors. In addition to its pipeline products, the Company's is also engaged in discovery research of CLD-301 (AAA) for tumor Indications.
About ACXP Acurx Pharmaceuticals Inc.
Acurx Pharmaceuticals Inc is a clinical stage biopharmaceutical company developing a new class of antibiotics for infections caused by bacteria listed as priority pathogens by the World Health Organization, Centers for Disease Control and Prevention and Food and Drug Administration. The company's approach is to develop antibiotic candidates with a Gram-positive selective spectrum. The Company's segment consists of the development of clinical and preclinical product candidates for the development of the Company's proprietary new therapies.